Skip to main content

SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 22, 2023.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 22, 2023 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rebound occurs at a similar rate for those receiving and not receiving oral antiviral treatment and for those receiving nirmatrelvir/ritonavir or placebo, according to research published in the Dec. 22 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Dallas J. Smith, Pharm.D., from the CDC in Atlanta, and colleagues reviewed SARS-CoV-2 rebound studies published during Feb. 1, 2020, to Nov. 29, 2023, to enhance current understanding of rebound. Seven studies met the inclusion criteria: one randomized trial and six observational studies, which compared rebound for those receiving and not receiving antiviral treatment. The researchers observed no significant differences in rebound rates for those receiving versus not receiving treatment in four studies, including the randomized trial. Outpatients who experienced rebound had no hospitalizations or deaths reported.

Patrick R. Harrington, Ph.D., from the U.S. Food and Drug Administration in Silver Spring, Maryland, and colleagues examined viral RNA shedding from two phase 2/3 placebo-controlled, randomized trials of nirmatrelvir/ritonavir to examine the role of treatment in COVID-19 rebound. The researchers found that patients receiving nirmatrelvir/ritonavir or placebo had similar rates of SARS-CoV-2 RNA shedding based on nasopharyngeal viral RNA levels from day 5 (end of treatment) to day 10 or day 14. Viral RNA rebound occurred in 6.4 to 8.4 percent of nirmatrelvir/ritonavir recipients and 5.9 to 6.5 percent of placebo recipients among those with a virologic response through day 5.

"These findings support FDA's determination of safety and efficacy of nirmatrelvir/ritonavir in eligible patients at high risk for severe COVID-19," Harrington and colleagues write.

Abstract/Full Text - Smith

Abstract/Full Text - Harrington

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Further Support and Information on COVID-19

Read this next

Some Children Prescribed Nonrecommended Meds for COVID-19

MONDAY, May 13, 2024 -- Despite national guidelines, a small proportion of children were prescribed ineffective and potentially harmful medications for acute COVID-19, according...

Following Drop After COVID-19 Onset, Inappropriate Antibiotic Prescribing Is Up

WEDNESDAY, May 1, 2024 -- There was an initial decrease in inappropriate antibiotic prescriptions following onset of COVID-19, followed by an increase, according to a study...

Long-Term Smell, but Not Taste, Deficits Seen After COVID-19

WEDNESDAY, May 1, 2024 -- Olfactory dysfunction, especially for smell, is more common in individuals with prior COVID-19 versus individuals with no history of infection, with...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.